Compare Abeona Therapeutics Inc (ABEO) vs Bank of America Corp (BAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bank of America Corp — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Bank of America Corp trades at $58.55 (market cap $424.80B). The key difference: Bank of America Corp is far larger — about 1137.9× Abeona Therapeutics Inc's market cap, and Bank of America Corp pays a 1.87% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BAC | |
|---|---|---|
Market Cap | $373.32M | $424.80B |
Sector | Health | Financials |
52-Week High | $7.23 | $59.90 |
52-Week Low | $4.17 | $44.92 |
Enterprise Value | $228.22M | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Bank of America (BAC) trades at $59.9, up 1.99% today, near the analyst consensus price target of $63.79. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels indicate potential overbought conditions. Fundamentally, BAC delivered three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.1 billion in 2025, and the net income margin improved to 26.97%. Recent news highlights strategic partnerships and a focus on talent acquisition.
BAC presents a favorable outlook with robust earnings growth, a dominant deposit franchise, and positive analyst sentiment (64.8% buy ratings). Key opportunities include potential capital returns post-stress tests and AI-driven efficiency gains. Risks involve interest rate sensitivity, macroeconomic pressures on lending, and regulatory changes. The stock's current valuation (P/E 14.86) appears reasonable relative to historical performance, supporting a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
